The IL-1 Antagonist Anakinra Attenuates Glioblastoma Aggressiveness by Dampening Tumor-Associated Inflammation

Background: The recombinant IL-1 receptor antagonist anakinra—currently approved for the treatment of autoinflammatory diseases—blocks IL-1β-mediated inflammatory signaling. As inflammation is a major driver of cancer, we hypothesized that anakinra might be able to mitigate glioblastoma (GBM) aggres...

Descripción completa

Detalles Bibliográficos
Autores principales: Hübner, Max, Effinger, David, Wu, Tingting, Strauß, Gabriele, Pogoda, Kristin, Kreth, Friedrich-Wilhelm, Kreth, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072290/
https://www.ncbi.nlm.nih.gov/pubmed/32069807
http://dx.doi.org/10.3390/cancers12020433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072290/
https://www.ncbi.nlm.nih.gov/pubmed/32069807
http://dx.doi.org/10.3390/cancers12020433

Ejemplares similares